Is it really possible to get diabetes after eating atorvastatin? See what the cardiovascular experts say

Atorvastatin and other statin lipid-lowering drugs have good lipid-lowering effect and can stabilize plaque to prevent vascular blockage. A large number of studies have shown that statin lipid-lowering drugs can significantly reduce diabetes patients and diabetes with coronary heart disease The risk of patients’ cardiovascular events, so these drugs are widely used in clinical practice, in addition to cardiovascular, neurology, endocrinology will often prescribe such drugs. However, some people say that eating atorvastatin may cause diabetes. is this real? What is the basis? Why may long-term atorvastatin cause new diabetes? Several studies have shown that statin and other statins such as atorvastatin can increase the risk of diabetes. The possible mechanisms are as follows: (1) Statins can affect insulin sensitivity and the process of cellular uptake of blood glucose: studies have shown that statins Lipid-lowering drugs can reduce insulin sensitivity, thereby affecting blood sugar control, leading to increased incidence of type 2 diabetes. Statin lipid-lowering drugs, in addition to affecting insulin sensitivity, can also directly affect the cellular uptake of blood glucose. (2) Statin lipid-lowering drugs affect insulin secretion through β-cells: statin lipid-lowering drugs can not only inhibit the direct action of HMG-COA (hydroxymethylglutaryl coenzyme A reductase) reductase, but also reduce the body Cholesterol reduces insulin secretion, which leads to new diabetes. (3) The role of genetic mutations to promote blood sugar increase: A medical team has deeply studied the mechanism of statin to increase blood sugar, and evaluated whether it is related to the direct inhibition of HMG-COA reductase by statins. The results of the study showed that when the mutation of the gene encoding HMG-COA caused the structure or function of HMG-CoA reductase to be inhibited, the blood glucose in the patient’s body increased. As a HMG-CoA reductase inhibitor, the statin tuned bamboo drug, which inhibits the function of HMG-CoA reductase, is likely to be one of the mechanisms leading to new-onset diabetes. Statin lipid-lowering drugs can cause abnormal blood sugar, should we stop statin lipid-lowering drugs? In most cases, it is not necessary. The reason is simple: weigh the pros and cons. The use of statins can avoid acute cardiovascular and cerebrovascular events. Compared with abnormal blood glucose or diabetes, the advantages are obviously greater than the disadvantages. In one study, after observing 225 patients taking statin lipid-lowering drugs for four years, it was found that for every 5.4 deaths or myocardial infarctions prevented and reduced by statin lipid-lowering drugs, only 1 case had new-onset diabetes. If the effect of statin lipid-lowering drugs on the prevention of stroke and coronary revascularization is considered, the benefit of statin lipid-lowering drugs in preventing cardiovascular events is significantly higher than the risk of statins leading to new diabetes. Therefore, it is still necessary to continue to use statin lipid-lowering drugs in people who are suitable for statin treatment. Especially for people with moderate to high cardiovascular risk and those with definite atherosclerotic cardiovascular disease, compared with cardiovascular benefit, statin lipid-lowering drugs cause little risk of new diabetes. Therefore, even if there is a clear blood sugar abnormality caused by a statin lipid-lowering drug, the statin lipid-lowering drug should still be used consistently. In conclusion, statins such as atorvastatin can significantly reduce the risk of cardiovascular events in diabetic patients. Although it may indeed increase blood sugar or cause new diabetes, this adverse effect is far lower than that of statins. Clinical benefit. But it also reminds us that it is best to monitor blood sugar levels before and during statin administration. At the same time, pay attention to the dosage when taking the medicine. Do not increase the dosage of the medicine by yourself in order to quickly reach the blood lipid standard. References Su Xin, Zhao Shuan. Research progress on the risk of statin-induced new-onset diabetes[J]. Chinese Journal of Cardiovascular Diseases, 2016, 44(5): 456-457. , Thank you for the picture author, if you find any violation of your copyright, please contact me, I will delete it.)